In Brief: Toxicity testing
Executive Summary
Toxicity testing: FDA guidance on "Single Dose Acute Toxicity Testing for Pharmaceuticals" published in the Aug. 26 Federal Register. The guidance is a modification of a draft guidance published as part of International Conference on Harmonization in April 1992 that sought to eliminate LD50 studies. FDA says modified document is not an ICH consensus position, but is in general agreement with ICH toxicity testing principles. The modified guidance provides information that "would allow for use of single-dose toxicity studies to support single dose studies in humans," agency says...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth